CT radiomics to predict Deauville score 4 positive and negative Hodgkin lymphoma manifestations.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 11 2022
21 11 2022
Historique:
received:
10
07
2022
accepted:
11
11
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
24
11
2022
Statut:
epublish
Résumé
18F-FDG-PET/CT is standard to assess response in Hodgkin lymphoma by quantifying metabolic activity with the Deauville score. PET/CT, however, is time-consuming, cost-extensive, linked to high radiation and has a low availability. As an alternative, we investigated radiomics from non-contrast-enhanced computed tomography (NECT) scans. 75 PET/CT examinations of 43 patients on two different scanners were included. Target lesions were classified as Deauville score 4 positive (DS4+) or negative (DS4-) based on their SUVpeak and then segmented in NECT images. From these segmentations, 107 features were extracted with PyRadiomics. All further statistical analyses were then performed scanner-wise: differences between DS4+ and DS4- manifestations were assessed with the Mann-Whitney-U-test and single feature performances with the ROC-analysis. To further verify the reliability of the results, the number of features was reduced using different techniques. The feature median showed a high sensitivity for DS4+ manifestations on both scanners (scanner A: 0.91, scanner B: 0.85). It furthermore was the only feature that remained in both datasets after applying different feature reduction techniques. The feature median from NECT concordantly has a high sensitivity for DS4+ Hodgkin manifestations on two different scanners and thus could provide a surrogate for increased metabolic activity in PET/CT.
Identifiants
pubmed: 36411307
doi: 10.1038/s41598-022-24227-0
pii: 10.1038/s41598-022-24227-0
pmc: PMC9678888
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20008Informations de copyright
© 2022. The Author(s).
Références
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3198-3220
pubmed: 33604689
Semin Nucl Med. 2018 Jan;48(1):76-81
pubmed: 29195620
Methods. 2021 Apr;188:105-111
pubmed: 32634555
Cancers (Basel). 2021 Jul 20;13(14):
pubmed: 34298847
Mol Imaging Biol. 2022 Aug;24(4):537-549
pubmed: 35031945
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Diagn Interv Radiol. 2016 Jan-Feb;22(1):35-9
pubmed: 26611258
Sci Rep. 2016 Mar 24;6:23428
pubmed: 27009765
EJNMMI Phys. 2020 Jan 10;7(1):2
pubmed: 31925574
J Nucl Med. 2021 Mar;62(3):338-341
pubmed: 32764122
Methods. 2021 Apr;188:20-29
pubmed: 32504782
Sci Rep. 2020 Jul 15;10(1):11649
pubmed: 32669642
EJNMMI Phys. 2019 May 10;6(1):8
pubmed: 31076884
J Nucl Med. 2007 Mar;48(3):471-80
pubmed: 17332626
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929
Radiology. 2018 Aug;288(2):407-415
pubmed: 29688159
Blood. 2018 Nov 22;132(21):2273-2279
pubmed: 30166329
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Leuk Lymphoma. 2009 Aug;50(8):1257-60
pubmed: 19544140
Eur Radiol. 2017 Mar;27(3):1012-1020
pubmed: 27380902
J Nucl Med. 2017 Feb;58(2):282-287
pubmed: 27660141
Sci Rep. 2021 Jan 21;11(1):2055
pubmed: 33479392
Mol Imaging Biol. 2018 Aug;20(4):641-649
pubmed: 29270848
Clin Nucl Med. 2019 Oct;44(10):e559-e565
pubmed: 31306204
Sci Rep. 2021 Dec 10;11(1):23812
pubmed: 34893676
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Sci Rep. 2019 Feb 4;9(1):1322
pubmed: 30718585
Sci Rep. 2022 Jun 17;12(1):10192
pubmed: 35715462
Med Phys. 2014 Dec;41(12):121904
pubmed: 25471964
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1301-8
pubmed: 24604592
Leuk Lymphoma. 2020 Dec;61(12):2923-2930
pubmed: 32654590
Sci Rep. 2018 Aug 29;8(1):13047
pubmed: 30158540